Singular Genomics Systems, Inc. OMIC
We take great care to ensure that the data presented and summarized in this overview for Singular Genomics Systems, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OMIC
Top Purchases
Top Sells
About OMIC
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
Insider Transactions at OMIC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2024
|
Andrew Spaventa Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
1,212
+0.85%
|
-
|
|
Nov 12
2024
|
Andrew Spaventa Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,212
-78.85%
|
-
|
|
Nov 12
2024
|
Andrew Spaventa Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
695
-31.14%
|
$15,290
$22.55 P/Share
|
|
Nov 12
2024
|
Andrew Spaventa Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,907
+46.07%
|
-
|
|
Nov 09
2024
|
Jyotsna Ghai Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+9.04%
|
-
|
|
Nov 09
2024
|
Eli N. Glezer Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+0.32%
|
-
|
|
Nov 09
2024
|
Dalen Meeter Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+5.44%
|
-
|
|
Oct 02
2024
|
Jyotsna Ghai Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,666
+42.37%
|
-
|
|
Sep 18
2024
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
32,000
+7.92%
|
$544,000
$17.21 P/Share
|
|
Sep 17
2024
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
40,000
+10.53%
|
$600,000
$15.33 P/Share
|
|
Sep 16
2024
|
Tang Kevin C |
BUY
Open market or private purchase
|
Indirect |
50,416
+14.39%
|
$604,992
$12.74 P/Share
|
|
Sep 15
2024
|
Andrew Spaventa Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
312
+0.22%
|
-
|
|
Sep 15
2024
|
Andrew Spaventa Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
312
-48.98%
|
-
|
|
Sep 15
2024
|
Andrew Spaventa Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
175
-21.55%
|
$2,100
$12.38 P/Share
|
|
Sep 15
2024
|
Andrew Spaventa Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
487
+37.49%
|
-
|
|
Sep 15
2024
|
Eli N. Glezer Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+0.16%
|
-
|
|
Sep 15
2024
|
Dalen Meeter Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
209
+2.49%
|
-
|
|
Aug 12
2024
|
Andrew Spaventa Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
1,225
+0.87%
|
-
|
|
Aug 12
2024
|
Andrew Spaventa Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
1,225
-79.03%
|
-
|
|
Aug 12
2024
|
Andrew Spaventa Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-30.52%
|
$4,767
$7.12 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 441K shares |
|---|---|
| Exercise of conversion of derivative security | 197K shares |
| Bona fide gift | 104K shares |
| Payment of exercise price or tax liability | 681 shares |
|---|---|
| Bona fide gift | 104K shares |
| Open market or private sale | 870 shares |